Customer Demand and Project Design
We discuss your research goals, target preferences, and project scope to design a customized experimental plan aligned with your needs.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
For more than ten years, Creative Biolabs has leveraged expertise in life sciences and a comprehensive suite of anti-virus drug discovery solutions. We are dedicated to pioneering the development of inhibitor or analogue-based anti-monkeypox agents, offering our clients robust and highly effective strategies to combat this significant global health challenge.
Monkeypox virus (MPXV) is a double-stranded DNA (dsDNA) virus belonging to the Orthopoxvirus genus, closely related to variola virus, the causative agent of smallpox. It is a zoonotic virus, primarily transmitted from animals to humans, and can spread between humans through close contact. The virus replicates in the host cell cytoplasm, utilizing a range of viral enzymes and proteins essential for its life cycle.
Fig.1 Replication cycle of a poxvirus.1
Inhibitor-based drug discovery for MPXV focuses on identifying molecules that specifically block the activity of crucial viral enzymes or disrupt essential protein-protein interactions. These inhibitors are designed to precisely fit into the active sites or binding pockets of viral targets, such as viral DNA polymerase or proteases. This approach offers high specificity, potent efficacy in halting viral replication, and allows for rational drug design based on the target's structure. Furthermore, the potential for repurposing existing drugs with known safety profiles can significantly accelerate development.
Analogue-based strategies involve the design and synthesis of compounds that mimic the natural building blocks of viral DNA or RNA, such as nucleosides or nucleotides. When these "faulty" analogues are incorporated into the viral genome during replication, they can lead to chain termination, preventing further elongation of the viral DNA strand. Alternatively, they may induce mutagenesis, introducing errors that render the viral genome non-functional, or directly inhibit the viral polymerase by competing with natural substrates. This approach has a proven track record in antiviral therapy.
Creative Biolabs provides comprehensive services for the discovery and development of anti-Monkeypox drugs, utilizing both inhibitor and analogue-based strategies. Our integrated approach combines cutting-edge technology with deep scientific expertise to deliver potent, specific, and safe antiviral candidates.
Our inhibitor-based services are designed to identify and optimize molecules that precisely target essential viral functions. We leverage advanced screening technologies and rational design principles to develop highly effective compounds.
We conduct high-throughput screening (HTS) of extensive chemical libraries against validated MPXV targets, including viral DNA polymerase, proteases, and enzymes involved in nucleotide metabolism. This involves biochemical and cell-based assays to identify initial hits and assess their inhibitory activity.
Utilizing crystallographic data and computational modeling, we design and optimize inhibitors with enhanced binding affinity and selectivity for MPXV targets.
This approach allows us to identify small, weakly binding fragments that can be grown or linked into potent lead compounds, offering a highly efficient path to novel inhibitors.
Promising inhibitor candidates are rigorously tested in relevant animal models of MPXV infection to evaluate their antiviral efficacy, pharmacokinetics, and safety profiles in a living system.
Our analogue-based services focus on synthesizing and evaluating novel nucleoside and nucleotide analogues designed to disrupt MPXV replication. We aim to develop compounds with improved potency, bioavailability, and reduced toxicity.
Our expert medicinal chemists design and synthesize a diverse array of novel nucleoside and nucleotide analogues, exploring various chemical modifications to optimize their antiviral properties.
We perform cell-based assays to assess the ability of synthesized analogues to inhibit MPXV replication in infected cell lines, measuring parameters such as viral load reduction and cytopathic effect.
Detailed studies are conducted to elucidate how analogues interfere with the viral life cycle, confirming their ability to act as chain terminators, mutagens, or polymerase inhibitors.
Selected analogue candidates undergo comprehensive pharmacokinetic studies and efficacy testing in animal models to determine their absorption, distribution, metabolism, excretion, and overall antiviral effectiveness in vivo.
We discuss your research goals, target preferences, and project scope to design a customized experimental plan aligned with your needs.
Upon final project design approval, a formal contract is signed, outlining deliverables, timelines, and terms. The project then officially commences.
Our dedicated team meticulously carries out agreed experimental procedures using state-of-the-art facilities, adhering to high scientific standards. Regular updates are provided throughout this phase.
All generated data undergoes rigorous analysis by our expert bioinformaticians and statisticians. Comprehensive reports are compiled, detailing methodologies, results, and interpretations.
Final reports and agreed-upon materials are delivered. We remain available for follow-up consultations, addressing questions or providing further guidance.
Click the button to contact us for service details and a custom quote.
Inhibitor and analogue-based strategies are pivotal in developing effective anti-MPXV therapeutics. These compounds can be applied in various scenarios, from treating active infections to potentially serving as post-exposure prophylaxis. Inhibitors can directly halt viral replication by targeting specific enzymes like the viral DNA polymerase, preventing the virus from multiplying within host cells.
Analogues, by mimicking natural building blocks, disrupt the integrity of the viral genome or interfere with its synthesis, leading to non-functional viral particles. Both approaches offer the potential for highly targeted interventions with reduced off-target effects, contributing significantly to outbreak management and patient care.
Targeted Precision
Our solutions focus on highly specific viral targets, minimizing off-target effects and enhancing drug safety.
Integrated Pipeline
We offer an end-to-end drug discovery workflow, from initial screening to preclinical validation, ensuring seamless project progression.
Advanced Technologies
Leveraging state-of-the-art HTS, SBDD, FBDD, and AI/ML platforms for efficient hit identification and lead optimization.
Expert Team
Our multidisciplinary team of seasoned biologists, chemists, and pharmacologists brings unparalleled expertise to every project.
Customized Solutions
Each service is meticulously tailored to meet your unique research objectives, ensuring maximum relevance and impact.
We primarily target essential viral enzymes crucial for the MPXV life cycle. Our focus includes the viral DNA polymerase, which is vital for genome replication, as well as viral proteases responsible for processing viral proteins. We also investigate enzymes involved in nucleotide metabolism and those critical for viral mRNA synthesis and modification, aiming to disrupt key pathways unique to the virus.
Our approach to ensuring high specificity involves a combination of rational drug design and rigorous screening. We utilize structure-based drug design (SBDD) to engineer compounds that precisely fit into the active sites of viral targets. This is complemented by comprehensive selectivity profiling against host enzymes and other non-target proteins to minimize off-target interactions and potential side effects.
We specialize in synthesizing a diverse range of nucleoside and nucleotide analogues. This includes both purine and pyrimidine analogues, with various modifications designed to enhance their incorporation into the viral genome or improve their inhibitory activity against viral polymerases. We focus on developing compounds with improved bioavailability and reduced toxicity profiles compared to existing options.
Absolutely. We offer comprehensive in vitro and in vivo efficacy testing services. Our in vitro capabilities include cell-based antiviral assays and biochemical assays to assess compound potency. For in vivo validation, we utilize relevant animal models of MPXV infection to evaluate the drug candidates' efficacy, pharmacokinetics, and safety in a living organism, providing a complete preclinical picture.
We integrate AI/ML algorithms to significantly accelerate and enhance various stages of drug discovery. These technologies are employed for predicting compound properties, identifying novel chemical scaffolds, optimizing lead compounds for potency and selectivity, and analyzing complex biological data. This allows for more efficient exploration of chemical space and faster identification of promising candidates.
Creative Biolabs is committed to providing a full range of inhibitor or analogue-based anti-monkeypox drug discovery solutions to meet your requirements from mechanical studies to clinical applications. Leveraging sophisticated high-throughput screening, artificial intelligence, and in vitro and in vivo platforms, we offer a full range of monkeypox products and inhibitor or analogue-based drug discovery solutions against monkeypox. For more information, please do not hesitate to contact us.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.